Dexamethasone Reduces Postoperative Emesis by Decreasing PGF2α and LTC4 Levels
This trial is active, not recruiting.
|Conditions||thyroid cancer, breast cancer|
|Start date||February 2011|
|End date||April 2013|
|Trial size||100 participants|
|Trial identifier||NCT01811199, 09.2011.0024|
Hypothesis: Dexamethasone reduces postoperative emesis in thyroidectomy and mastectomy patients.
|Observational model||case control|
Number of participants will be evaluated to show effect of dexamethasone in reducing postoperative emesis
time frame: up to 3 days
Male or female participants from 18 years up to 65 years old.
Inclusion Criteria: - breast and thyroid cancer patients no neoadjuvant treated no NSAID or steroid usage heallthy volunteers, signed the informed consent Exclusion Criteria: - ones who did not sign the consent form NSAID or steroid users
|Official title||Dexamethasone Reduces Postoperative Emesis by Decreasing PGF2α and LTC4 Levels|
|Principal investigator||A.Ozdemir Aktan, MD,prof|
|Description||This study has been done to further study the effectiveness of dexamethasone in the prevention of postoperative emesis after breast and thyroid surgery and at the same time, the mechanism of action was investigated. In this prospective, randomized controlled trial it was hypothesized that corticosteroids exert their antiemetic effects in postoperative period via plasma prostaglandin F2 alpha (PGF2 α) and plasma leukotriene C4 (LTC4) inhibition.|
Call for more information